title: Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
authors.forename: L C
authors.initials: LC
authors.lastname: Coates
authors.forename: D G
authors.initials: DG
authors.lastname: McGonagle
authors.forename: A N
authors.initials: AN
authors.lastname: Bennett
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: H
authors.initials: H
authors.lastname: Marzo-Ortega
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000150:complications* / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000139:chemically induced* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept